Brief: GRI Bio Reports 6-Week Interim Biomarker Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis (“Ipf”)
31/07/2025 15:03
July 31 (Reuters) - GRI Bio Inc GRI.O: GRI BIO REPORTS 6-WEEK INTERIM BIOMARKER DATA IN ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”) GRI BIO INC - TOPLINE RESULTS FROM PHASE 2A BIOMARKER STUDY EXPECTED Q3 2025 GRI BIO INC - IDMC RECOMMENDS CONTINUATION OF STUDY WITH NO SAFETY CONCERNS GRI BIO INC - PHASE 2A STUDY FULLY ENROLLED; TOPLINE DATA EXPECTED Q3 2025 Source text: ID:nGNX3DRkST Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027